ZA200300253B - Methods of treating cancer and the pain associated therewith with using endothelin antagonists. - Google Patents
Methods of treating cancer and the pain associated therewith with using endothelin antagonists. Download PDFInfo
- Publication number
- ZA200300253B ZA200300253B ZA200300253A ZA200300253A ZA200300253B ZA 200300253 B ZA200300253 B ZA 200300253B ZA 200300253 A ZA200300253 A ZA 200300253A ZA 200300253 A ZA200300253 A ZA 200300253A ZA 200300253 B ZA200300253 B ZA 200300253B
- Authority
- ZA
- South Africa
- Prior art keywords
- substance
- composition
- patient
- loweralkyl
- alkylene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63338900A | 2000-08-07 | 2000-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300253B true ZA200300253B (en) | 2004-11-17 |
Family
ID=24539436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300253A ZA200300253B (en) | 2000-08-07 | 2003-01-09 | Methods of treating cancer and the pain associated therewith with using endothelin antagonists. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1347751B1 (enExample) |
| JP (3) | JP4217068B2 (enExample) |
| KR (1) | KR20030027007A (enExample) |
| CN (1) | CN1635878A (enExample) |
| AR (1) | AR031122A1 (enExample) |
| AT (1) | ATE465728T1 (enExample) |
| AU (2) | AU2001281134B2 (enExample) |
| BG (1) | BG107577A (enExample) |
| BR (1) | BR0108865A (enExample) |
| CA (1) | CA2416879C (enExample) |
| DE (1) | DE60141979D1 (enExample) |
| HU (1) | HUP0302977A2 (enExample) |
| IL (1) | IL153769A0 (enExample) |
| MX (1) | MXPA03000984A (enExample) |
| NO (1) | NO20030593D0 (enExample) |
| NZ (1) | NZ523562A (enExample) |
| PE (1) | PE20020273A1 (enExample) |
| PL (1) | PL366160A1 (enExample) |
| SK (1) | SK1782003A3 (enExample) |
| TW (1) | TWI306760B (enExample) |
| WO (1) | WO2002011713A2 (enExample) |
| ZA (1) | ZA200300253B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| PL1765391T3 (pl) * | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Kompozycje bakteryjne do leczenia nowotworów |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
| ES2645509T3 (es) | 2010-07-26 | 2017-12-05 | Qu Biologics Inc | Composiciones antiinflamatorias inmunogénicas |
| CN102485238A (zh) * | 2010-12-06 | 2012-06-06 | 陈炯华 | 芎芷镇痛方 |
| CA3254723A1 (en) | 2014-05-02 | 2025-04-15 | Qu Biologics Inc | ANTIMICROBIAL IMMUNOMODULATION |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063911A (en) * | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
| NZ330818A (en) * | 1996-02-13 | 2000-05-26 | Abbott Lab | Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists |
| TR200101234T2 (tr) | 1997-08-04 | 2002-06-21 | Abbott Laboratories | Endotelin antagonistleri. |
| AU4382499A (en) * | 1998-12-11 | 2000-07-03 | Mactapes Limited | Curtain heading tape manufacture |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
-
2001
- 2001-07-24 TW TW090118053A patent/TWI306760B/zh active
- 2001-08-06 CA CA002416879A patent/CA2416879C/en not_active Expired - Fee Related
- 2001-08-06 WO PCT/US2001/024716 patent/WO2002011713A2/en not_active Ceased
- 2001-08-06 IL IL15376901A patent/IL153769A0/xx unknown
- 2001-08-06 SK SK178-2003A patent/SK1782003A3/sk unknown
- 2001-08-06 AT AT01959595T patent/ATE465728T1/de not_active IP Right Cessation
- 2001-08-06 CN CNA018169929A patent/CN1635878A/zh active Pending
- 2001-08-06 AR ARP010103755A patent/AR031122A1/es not_active Application Discontinuation
- 2001-08-06 AU AU2001281134A patent/AU2001281134B2/en not_active Ceased
- 2001-08-06 AU AU8113401A patent/AU8113401A/xx active Pending
- 2001-08-06 DE DE60141979T patent/DE60141979D1/de not_active Expired - Lifetime
- 2001-08-06 EP EP01959595A patent/EP1347751B1/en not_active Expired - Lifetime
- 2001-08-06 PE PE2001000782A patent/PE20020273A1/es not_active Application Discontinuation
- 2001-08-06 PL PL01366160A patent/PL366160A1/xx unknown
- 2001-08-06 HU HU0302977A patent/HUP0302977A2/hu unknown
- 2001-08-06 JP JP2002517050A patent/JP4217068B2/ja not_active Expired - Fee Related
- 2001-08-06 BR BR0108865-3A patent/BR0108865A/pt not_active Application Discontinuation
- 2001-08-06 NZ NZ523562A patent/NZ523562A/en unknown
- 2001-08-06 KR KR10-2003-7001735A patent/KR20030027007A/ko not_active Ceased
- 2001-08-06 MX MXPA03000984A patent/MXPA03000984A/es active IP Right Grant
-
2003
- 2003-01-09 ZA ZA200300253A patent/ZA200300253B/en unknown
- 2003-02-06 NO NO20030593A patent/NO20030593D0/no not_active Application Discontinuation
- 2003-02-21 BG BG107577A patent/BG107577A/bg unknown
-
2006
- 2006-11-08 JP JP2006302713A patent/JP2007084564A/ja active Pending
- 2006-11-08 JP JP2006302712A patent/JP2007063288A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI306760B (en) | 2009-03-01 |
| CA2416879C (en) | 2006-11-07 |
| CA2416879A1 (en) | 2002-02-14 |
| JP2007084564A (ja) | 2007-04-05 |
| WO2002011713A2 (en) | 2002-02-14 |
| AU8113401A (en) | 2002-02-18 |
| DE60141979D1 (de) | 2010-06-10 |
| MXPA03000984A (es) | 2003-09-05 |
| PE20020273A1 (es) | 2002-04-16 |
| EP1347751B1 (en) | 2010-04-28 |
| IL153769A0 (en) | 2003-07-06 |
| BR0108865A (pt) | 2005-04-19 |
| NO20030593L (no) | 2003-02-06 |
| JP2004520266A (ja) | 2004-07-08 |
| HUP0302977A2 (hu) | 2003-12-29 |
| NZ523562A (en) | 2006-10-27 |
| NO20030593D0 (no) | 2003-02-06 |
| BG107577A (bg) | 2003-10-31 |
| EP1347751A2 (en) | 2003-10-01 |
| WO2002011713A3 (en) | 2003-07-17 |
| SK1782003A3 (en) | 2003-08-05 |
| ATE465728T1 (de) | 2010-05-15 |
| CN1635878A (zh) | 2005-07-06 |
| AR031122A1 (es) | 2003-09-10 |
| AU2001281134B2 (en) | 2005-06-09 |
| JP4217068B2 (ja) | 2009-01-28 |
| JP2007063288A (ja) | 2007-03-15 |
| KR20030027007A (ko) | 2003-04-03 |
| PL366160A1 (en) | 2005-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020055457A1 (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
| CN105873440B (zh) | 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 | |
| EA029072B1 (ru) | Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты | |
| CA2416879C (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
| US20230119759A1 (en) | Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound | |
| AU2001281134A1 (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
| KR20020075797A (ko) | 엔도텔린 유발성 질환 치료제 | |
| RU2320339C2 (ru) | Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы | |
| KR20200017487A (ko) | 비알코올성 지방간염 치료를 위한 리코플리고진 | |
| AU2019352068B9 (en) | Combinations with a C-19 steroid for treating cancers | |
| JPWO2004035089A1 (ja) | ホルモン依存性癌の治療剤 | |
| US20050261246A1 (en) | Methods for treating inflammatory and autoimmune diseases | |
| CA2555850A1 (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
| CZ106098A3 (cs) | Použití benzothiofenu k přípravě farmaceutického prostředku k inhibici inhibitoru 1 plasminogenového aktivátoru | |
| US12427142B2 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| NZ294123A (en) | Use of a 2-phenyl-3-phenylcarbonyl-benzothiophene derivative for inhibiting endometrial mitoses | |
| WO2021048419A1 (en) | Combination therapies comprising trametinib for the treatment of cholangiocarcinoma | |
| CA3240454A1 (en) | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibito | |
| AU2022342537A1 (en) | Pharmaceutical composition for treating solid tumors | |
| WO2023175477A1 (en) | Treatment of breast cancer with amcenestrant | |
| WO2025162173A1 (zh) | 治疗经cdk4/6抑制剂治疗后的乳腺癌用途 | |
| JP2006504750A (ja) | ブドウ膜黒色腫の処置 | |
| WO1997018819A1 (en) | Antineoplastic methods and compositions employing optically pure (-)-fotemustine |